Highlights CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-20 pm EDT			5-day change	1st Jan Change
5.440 ^USD	-0.91%		-2.33%	+59.53%

Jun. 16	CureVac agrees to pay Biontech termination fee Of $43.8 mln under specified circumstances	RE
Jun. 13	Jefferies Downgrades CureVac to Hold From Buy, $5 Price Target	MT

Highlights

Deals of the day-Mergers and acquisitions	Jun. 12	RE
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals	Jun. 12	RE
Top Midday Gainers	Jun. 12	MT
Sector Update: Health Care	Jun. 12	MT
Top Midday Stories: Boeing Shares Fall After Air India Plane Crash; Oracle Q4 Results Top Expectations	Jun. 12	MT
Deals of the day-Mergers and acquisitions	Jun. 12	RE
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals	Jun. 12	RE
Sector Update: Health Care	Jun. 12	MT
US Equity Futures Decline as Trump Talks Tough on Trade	Jun. 12	MT
BioNTech to Acquire CureVac in $1.25 Billion All-Stock Deal	Jun. 12	MT
German economy ministry says it supports BioNTech/CureVac transaction	Jun. 12	RE
Top Premarket Gainers	Jun. 12	MT
BioNTech, CureVac Agree to All-stock Purchase Deal	Jun. 12	MT
BioNTech to Buy CureVac in All-Stock Deal	Jun. 12	MT
BioNTech to Acquire CureVac in All-Stock Deal	Jun. 12	MT
BioNTech agrees to acquire former COVID vaccine rival CureVac	Jun. 12	RE
Biontech Announces Strategic Transaction To Acquire Curevac In Public Exchange Offer	Jun. 12	RE
BioNTech SE entered into a definitive Purchase Agreement to acquire CureVac N.V. from dievini Hopp BioTech holding GmbH & Co. KG, Qatar Holding LLC, KfW and others.	Jun. 11	CI
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 20	CI
Curevac Q1 Revenue Eur 900 Thousand	May. 20	RE
CUREVAC : 2025 will be less costly	Apr. 11
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 11	CI
CureVac's Early-stage Trial of Lung Cancer Drug Gets US FDA Clearance	Apr. 07	MT
CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy	Apr. 07	MT
CureVac N.V. Receives U.S. FDA Ind Clearance to Initiate Phase 1 Clinical Trial for Novel Mrna-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer	Apr. 07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

CUREVAC : Successful cash burn reduction

June 01, 2025 at 10:14 am EDT